18.11

2.72% 0.48

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $18.11, with a volume of 1.01M. It is up +2.72% in the last 24 hours and down -2.37% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Previous Close:

$17.63

Open:

$17.46

24h Volume:

1.01M

Relative Volume:

1.09

Market Cap:

$2.03B

Revenue:

$14.09M

Net Income/Loss:

$-176.94M

P/E Ratio:

-8.4233

EPS:

-2.15

Net Cash Flow:

$-141.24M

1W Performance:

+2.84%

1M Performance:

-2.37%

6M Performance:

-8.77%

1Y Performance:

-2.21%

1-Day Range:

$16.95

$18.26

1-Week Range:

$16.79

$18.26

52-Week Range:

$14.06

$27.29

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	18.11	1.98B	14.09M	-176.94M	-141.24M	-2.15
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

May 31, 2025

Northern Trust Corp Takes $556,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

May 31, 2025

May 30, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Rating Increased to Hold at Wall Street Zen - Defense World

May 30, 2025

May 29, 2025

(NAMSW) Proactive Strategies - news.stocktradersdaily.com

May 29, 2025

Shareholders Will Probably Not Have Any Issues With NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) CEO Compensation - simplywall.st

May 29, 2025

May 27, 2025

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - GlobeNewswire

May 27, 2025

NewAmsterdam Pharma CEO to Present at William Blair, Jefferies, and Goldman Sachs Healthcare Conferences - Stock Titan

May 27, 2025

May 25, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Recommendation of “Buy” by Analysts - Defense World

May 25, 2025

May 24, 2025

(NAMS) Technical Pivots with Risk Controls - news.stocktradersdaily.com

May 24, 2025

May 23, 2025

NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market By Investing.com - Investing.com South Africa

May 23, 2025

NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market - Investing.com Canada

May 23, 2025

May 22, 2025

35,657 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by BNP Paribas Financial Markets - Defense World

May 22, 2025

May 20, 2025

Financial Contrast: NewAmsterdam Pharma (NAMS) versus Its Rivals - Defense World

May 20, 2025

May 19, 2025

(NAMSW) Investment Analysis - news.stocktradersdaily.com

May 19, 2025

The Manufacturers Life Insurance Company Purchases New Position in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

May 19, 2025

May 15, 2025

Tower Research Capital LLC TRC Sells 6,485 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

May 15, 2025

May 14, 2025

Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know - MSN

May 14, 2025

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference - GlobeNewswire

May 14, 2025

NewAmsterdam Pharma Showcases Non-Statin CVD Pipeline at Major RBC Healthcare Conference - Stock Titan

May 14, 2025

May 13, 2025

(NAMS) Proactive Strategies - news.stocktradersdaily.com

May 13, 2025

Analysts Have Been Trimming Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Price Target After Its Latest Report - simplywall.st

May 13, 2025

May 10, 2025

Barclays PLC Buys 9,117 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

May 10, 2025

Needham & Company LLC Issues Pessimistic Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World

May 10, 2025

NewAmsterdam Pharma First Quarter 2025 Earnings: US$0.34 loss per share (vs US$1.06 loss in 1Q 2024) - Yahoo Finance

May 10, 2025

May 09, 2025

NewAmsterdam Pharma Reports Q1 2025 Financial Results - TipRanks

May 09, 2025

May 08, 2025

NewAmsterdam Pharma Q1 Net Loss Narrows, Revenue Rises - marketscreener.com

May 08, 2025

NewAmsterdam Pharma Company NV reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2025

NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025